^
    10d
    CDAK539A12303: A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior treatment with a Janus kinase inhibitor. (2025-523555-66-00)
    P2/3, N=60, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    1m
    Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment (clinicaltrials.gov)
    P1, N=24, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pelabresib (DAK539)
    1m
    A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    pelabresib (DAK539)
    1m
    Targeted treatment of anemia in Myelofibrosis and the impact of jak inhibitors. (PubMed, Expert Opin Pharmacother)
    Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xpovio (selinexor) • Reblozyl (luspatercept-aamt) • Ojjaara (momelotinib) • pelabresib (DAK539) • elritercept (KER-050)
    1m
    Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    pelabresib (DAK539)
    1m
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=6, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    2ms
    MANIFEST-3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (clinicaltrials.gov)
    P3, N=460, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    2ms
    CDAK539A12102: A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer (2025-521000-22-00)
    P1, N=9, Not yet recruiting, Novartis Pharma AG
    New P1 trial
    |
    pelabresib (DAK539) • midazolam hydrochloride
    2ms
    CDAK539A12103: A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer (2025-521001-40-00)
    P1, N=9, Not yet recruiting, Novartis Pharma AG
    New P1 trial
    |
    pelabresib (DAK539)
    2ms
    A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2029 --> Apr 2028 | Trial primary completion date: Nov 2029 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    pelabresib (DAK539)
    2ms
    Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2027 --> Nov 2026
    Trial primary completion date
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    4ms
    Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    pelabresib (DAK539)